Supplier Briefs: September 2016

552
Supplier Briefs

East Windsor, NJ-based Sabinsa Corporation now uses a “conclusive test to guarantee” its Curcumin C3 Complex products are all of natural origin. The firm says synthetic turmeric extract has been infiltrating the market, and its radio-carbon testing for all batches of Curcumin C3 Complex will help determine natural authenticity.

Krill and marine oils specialist, formerly Neptune Technologies and Bioressources, based in Laval, QC, Canada, is repositioning itself following the acquisition of Biodroga, as Neptune Wellness Solutions. The name is reflective of the company’s vision to “provide great nutrition solutions that deliver optimal health and wellness.” The firm is also relaunching its website, www.neptunecorp.com and debuting a new corporate logo.

PLT Health Solutions, Inc. of Morristown, NJ has published a new claims dossier for its Synapsa memory support ingredient derived from Bacopa monnieri. TAP-ROOT of NJ reviewed the science behind the claims.

NattoPharma, with U.S. headquarters in Metuchen, NJ, received a new U.S. patent (#9364447) that lets the firm say vitamin K as MK-7 inhibits or reduces age-related hardening of the arteries in people with cardiovascular conditions.

New data from an in vitro study was presented at the International Society of Sports Nutrition 13th Annual Conference suggesting, “Nitrosigine bonded arginine silicate
supplementation significantly increased nitric oxide (NO) production.” This ingredient, marketed by Nutrition 21 of Purchase, NY, had five times better production of NO compared with other ingredients like l-arginine and l-citrulline.

Gelita AG received the German Brand Award for successful brand management from the German Design Council and the German Brand Institute. In addition, Gelita’s corporate film, “You Can See,” won the gold Intermedia-globe Award in gold at the World Media Festival.

ExcelVite, with U.S. offices in Edison, NJ, started a new human clinical trial on EVNol SupraBio full spectrum palm tocotrienol complex. Conducted at Ohio State University Medical Center, the NUTRITION Phase II human clinical trial will assess the blood-thinning and cholesterol-lowering properties of palm tocotrienol complex (400 or 800 mg) in 300 people who have had strokes or mini-strokes and are undergoing standard treatment for the prevention of recurrent stroke. Phase I started in 2012 and examined the ingredient’s role in in platelet function and blood lipid profile in ischemic stroke event.

Healthy Food Ingredients (HFI) of Fargo, SD, acquired Heartland Flax. The deal will close this fall.

Published in WholeFoods Magazine September 2016